Hypercholesterolemia Clinical Trial
Official title:
Endurance Training and Post-exercise Low Glycemic Index Recovery Diet for Improving Postprandial Triglycerides
NCT number | NCT03587051 |
Other study ID # | 17-171 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 15, 2018 |
Est. completion date | December 30, 2019 |
Verified date | June 2020 |
Source | University of Saskatchewan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postprandial triglycerides are a strong risk factor for heart disease. The purpose is to assess the effects of a low-glycemic versus high-glycemic meal after 90 minute exercise sessions that are done 4 times a week for 6 weeks on postprandial triglyceride level. Secondary measurements include other lipids and body composition.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 30, 2019 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 44 Years |
Eligibility |
Inclusion Criteria: - Overweight or obese (BMI 25 or greater) Exclusion Criteria: - Smokers - Diabetic - Taking medications that affect carbohydrate or lipid metabolism |
Country | Name | City | State |
---|---|---|---|
Canada | University of Saskatchewan | Saskatoon | Saskatchewan |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan | Heart and Stroke Foundation of Canada |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postprandial triglycerides | Triglyceride from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial cholesterol | Cholesterol from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial low density lipoprotein | Low density lipoprotein from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial high density lipoprotein | High density lipoprotein from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial glucose | Glucose from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial insulin | Insulin from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting Triglyceride | Triglyceride from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting cholesterol | Cholesterol from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting LDL-cholesterol | LDL from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting HDL-cholesterol | HDL from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting glucose | Glucose from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Fasting Insulin | Insulin from serum | Change from baseline to 1 week and 6 weeks | |
Secondary | Postprandial fat oxidation | Fat oxidation assessed by expiratory gases | Change from baseline to 1 week and 6 weeks | |
Secondary | Fat mass | Fat mass assessed by dual energy x-ray absorptiometry | Change from baseline to 6 weeks | |
Secondary | Waist Girth | Waist girth assessed by a measurement tape | Change from baseline to 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
Completed |
NCT01478789 -
Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans
|
N/A | |
Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A |